Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 1
1968 1
1969 2
1970 1
1971 2
1972 1
1978 1
1981 1
1982 3
1983 2
1984 7
1985 9
1986 11
1987 4
1988 13
1989 9
1990 10
1991 18
1992 10
1993 14
1994 15
1995 17
1996 15
1997 12
1998 13
1999 14
2000 15
2001 15
2002 17
2003 27
2004 18
2005 11
2006 11
2007 21
2008 19
2009 20
2010 16
2011 18
2012 22
2013 16
2014 32
2015 30
2016 17
2017 25
2018 28
2019 26
2020 33
2021 27
2022 21
2023 18
2024 18
2025 19
2026 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

700 results

Results by year

Filters applied: . Clear all
Page 1
Comprehensive molecular and clinical findings in 29 patients with multi-locus imprinting disturbance.
Urakawa T, Soejima H, Yamoto K, Hara-Isono K, Nakamura A, Kawashima S, Narusawa H, Kosaki R, Nishimura Y, Yamazawa K, Hattori T, Muramatsu Y, Inoue T, Matsubara K, Fukami M, Saitoh S, Ogata T, Kagami M. Urakawa T, et al. Among authors: muramatsu y. Clin Epigenetics. 2024 Oct 5;16(1):138. doi: 10.1186/s13148-024-01744-5. Clin Epigenetics. 2024. PMID: 39369220 Free PMC article.
Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).
Nagai SE, Hattori M, Yoshinami T, Masuda H, Okamura T, Watanabe K, Nakayama T, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Sasada S, Ishida T, Futamura M, Muramatsu Y, Kosaka N, Masuda N. Nagai SE, et al. Among authors: muramatsu y. Breast Cancer. 2025 Jul;32(4):705-715. doi: 10.1007/s12282-025-01689-4. Epub 2025 Apr 5. Breast Cancer. 2025. PMID: 40186791 Free PMC article.
Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial).
Sato Y, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Ando M, Tsuda K, Iwata O, Muramatsu Y, Kidokoro H, Hirakawa A, Hayakawa M; SHEILD team. Sato Y, et al. Among authors: muramatsu y. Stem Cells Transl Med. 2024 Nov 12;13(11):1053-1066. doi: 10.1093/stcltm/szae071. Stem Cells Transl Med. 2024. PMID: 39401019 Free PMC article.
Ehrlichia ruminantium, Sudan.
Muramatsu Y, Ukegawa SY, Rahim A, El Hussein M, Abdel Rahman MB, Abdel Gabbar KM, Chitambo AM, Komiya T, Mwase ET, Morita C, Tamura Y. Muramatsu Y, et al. Emerg Infect Dis. 2005 Nov;11(11):1792-3. doi: 10.3201/eid1111.050744. Emerg Infect Dis. 2005. PMID: 16422005 Free PMC article. No abstract available.
Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 - advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26).
Bando H, Ueda A, Terata K, Doi M, Nagai SE, Hattori M, Watanabe K, Tamura N, Futamura M, Koizumi K, Niikura N, Miyaji T, Muramatsu Y, Xu L, Masuda N, Saji S. Bando H, et al. Among authors: muramatsu y. Breast Cancer. 2025 Sep;32(5):1132-1143. doi: 10.1007/s12282-025-01744-0. Epub 2025 Jul 18. Breast Cancer. 2025. PMID: 40681949 Free PMC article.
[FSS and SAS].
Muramatsu Y, Muramatsu K, Majima I. Muramatsu Y, et al. Nihon Rinsho. 2009 Sep;67(9):1695-700. Nihon Rinsho. 2009. PMID: 19768903 Review. Japanese.
700 results